Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
University of Toronto
$70,000.00
Role of Intestinal Drug Transporters and Metabolic Enzymes in Antiretroviral Drug-Drug Interactions
EF 2010-11
Résumé
Highly active antiretroviral therapy (HAART), combining three or more anti-HIV drugs, constitutes a major progress in HIV treatment, which dramatically increased the life span of patients living with HIV. However, several issues related to the use of multiple drugs, i.e., toxicities, adverse effects, and drug-drug interactions, have made HAART implementation difficult in many patients. Many anti-HIV drugs have altered intestinal absorption in the presence of other drugs. Although the cause of these interactions is still unclear, intestinal drug carriers (transporters) and drug-metabolizing enzymes are believed to play a role. The intestine is also a major site for HIV replication, leading to the formation of a viral reservoir and the development of HIV-related gut pathology, barrier damage, and inflammation. These pathways alter the levels of intestinal drug transporters/enzymes in other disease states, but have not been examined in relation to HIV. We propose that i) anti-HIV drug interactions are in part mediated by intestinal drug transporters; and ii) HIV infection and/or anti-HIV therapy can alter the expression levels of intestinal transporters and enzymes. We propose to use Caco-2 cell system, an established model for the human intestine, to examine the role of drug transporters in the absorption of anti-HIV drugs and drug-drug interactions. The uptake of anti-HIV drugs across the intestinal tissue will also be assessed to determine whether the absorption of anti-HIV drugs is altered by co-administered drugs. We will also determine the effect of HIV infection or anti-HIV therapy on transporter/enzyme expression levels in intestinal biopsy samples obtained from HIV patients (pre- and post-HAART) and healthy individuals (controls). This knowledge will further our understanding of intestinal absorption and drug-drug interactions of anti-HIV drugs, and has a potential to improve current HIV pharmacotherapy and the quality of life of people living with HIV.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
229694
Name
Kis Olena
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Role of Intestinal Drug Transporters and Metabolic Enzymes in Antiretroviral Drug-Drug Interactions
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$70,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Antiretroviral Therapy; Caco-2 Drug Permeability Assay; Drug Metabolism; Drug Transport; Drug-Drug Interactions; Gastrointestinal Mucosa; Hiv/Aids; Human Intestinal Biopsies; In Situ Intestinal Perfusion; Pharmacokinetics
Abstract
Highly active antiretroviral therapy (HAART), combining three or more anti-HIV drugs, constitutes a major progress in HIV treatment, which dramatically increased the life span of patients living with HIV. However, several issues related to the use of multiple drugs, i.e., toxicities, adverse effects, and drug-drug interactions, have made HAART implementation difficult in many patients. Many anti-HIV drugs have altered intestinal absorption in the presence of other drugs. Although the cause of these interactions is still unclear, intestinal drug carriers (transporters) and drug-metabolizing enzymes are believed to play a role. The intestine is also a major site for HIV replication, leading to the formation of a viral reservoir and the development of HIV-related gut pathology, barrier damage, and inflammation. These pathways alter the levels of intestinal drug transporters/enzymes in other disease states, but have not been examined in relation to HIV. We propose that i) anti-HIV drug interactions are in part mediated by intestinal drug transporters; and ii) HIV infection and/or anti-HIV therapy can alter the expression levels of intestinal transporters and enzymes. We propose to use Caco-2 cell system, an established model for the human intestine, to examine the role of drug transporters in the absorption of anti-HIV drugs and drug-drug interactions. The uptake of anti-HIV drugs across the intestinal tissue will also be assessed to determine whether the absorption of anti-HIV drugs is altered by co-administered drugs. We will also determine the effect of HIV infection or anti-HIV therapy on transporter/enzyme expression levels in intestinal biopsy samples obtained from HIV patients (pre- and post-HAART) and healthy individuals (controls). This knowledge will further our understanding of intestinal absorption and drug-drug interactions of anti-HIV drugs, and has a potential to improve current HIV pharmacotherapy and the quality of life of people living with HIV.
Competitiondate
201010
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Kis, Olena
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $70,000~ $0~